269 related articles for article (PubMed ID: 36389667)
21. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
He Y; Bouwstra R; Wiersma VR; de Jong M; Jan Lourens H; Fehrmann R; de Bruyn M; Ammatuna E; Huls G; van Meerten T; Bremer E
Nat Commun; 2019 Feb; 10(1):533. PubMed ID: 30710089
[TBL] [Abstract][Full Text] [Related]
22. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
[TBL] [Abstract][Full Text] [Related]
23. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
24. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
25. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
Yang H; Yan M; Li W; Xu L
J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
[TBL] [Abstract][Full Text] [Related]
26. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.
Zhu D; Hadjivassiliou H; Jennings C; Mikolon D; Ammirante M; Acharya S; Lloyd J; Abbasian M; Narla RK; Piccotti JR; Stamp K; Cho H; Hariharan K
MAbs; 2024; 16(1):2310248. PubMed ID: 38349008
[TBL] [Abstract][Full Text] [Related]
27. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
[TBL] [Abstract][Full Text] [Related]
28. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
[TBL] [Abstract][Full Text] [Related]
29. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
30. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Barkal AA; Weiskopf K; Kao KS; Gordon SR; Rosental B; Yiu YY; George BM; Markovic M; Ring NG; Tsai JM; McKenna KM; Ho PY; Cheng RZ; Chen JY; Barkal LJ; Ring AM; Weissman IL; Maute RL
Nat Immunol; 2018 Jan; 19(1):76-84. PubMed ID: 29180808
[TBL] [Abstract][Full Text] [Related]
31. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.
Zhao J; Zhong S; Niu X; Jiang J; Zhang R; Li Q
Scand J Immunol; 2019 Nov; 90(5):e12804. PubMed ID: 31267559
[TBL] [Abstract][Full Text] [Related]
32. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
33. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
34. Macrophages are critical effectors of antibody therapies for cancer.
Weiskopf K; Weissman IL
MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
[TBL] [Abstract][Full Text] [Related]
35. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
[TBL] [Abstract][Full Text] [Related]
36. Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.
van Rees DJ; Brinkhaus M; Klein B; Verkuijlen P; Tool ATJ; Schornagel K; Treffers LW; van Houdt M; Kater AP; Vidarsson G; Gennery AR; Kuijpers TW; van Bruggen R; Matlung HL; van den Berg TK
Blood Adv; 2022 Apr; 6(7):2156-2166. PubMed ID: 34942000
[TBL] [Abstract][Full Text] [Related]
37. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
[TBL] [Abstract][Full Text] [Related]
38. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
39. SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells.
Bahri M; Kailayangiri S; Vermeulen S; Galopin N; Rossig C; Paris F; Fougeray S; Birklé S
Cancer Immunol Immunother; 2022 Jan; 71(1):71-83. PubMed ID: 34023958
[TBL] [Abstract][Full Text] [Related]
40. SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients.
Chen YE; Burgess M; Mapp S; Mollee P; Gill D; Blumenthal A; Saunders NA
Front Immunol; 2020; 11():610523. PubMed ID: 33552071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]